Beta Drugs Limited has informed the Exchange about Presentation
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beta Drugs Limited shared its FY25 investor presentation highlighting total revenue of ₹362.36 Cr, up 23% year-on-year, with EBITDA (excluding exceptional items) of ₹81.04 Cr growing 32% and PAT of ₹45.8 Cr up 26%. The domestic own-brand oncology business crossed the ₹100 Cr milestone, while the international business grew 73% and now spans 46+ countries. Gross margin improved to 41.5% and EPS rose to ₹42.02 from ₹37.9. The company has set a multi-year revenue roadmap targeting ₹450+ Cr by FY26, with a pipeline of 25+ product launches over the next 3 years and 600+ registrations in the pipeline, supported by a sharp increase in cash and borrowings following a preferential issue to fund organic and inorganic growth.
For shareholders, the presentation signals strong operational momentum, improving margins, and a credible growth runway into FY26, though the sizeable jump in borrowings (from ₹11 Cr to ₹136.38 Cr) alongside a capital raise warrants a watch on how efficiently the fresh funds are deployed for expansion.